EP0646010A4 - Verwendung von müllerscher inhibierender substanz zur behandlung von tumoren und zur modulation der expression von klasse 1-haupthistokompatibilitätsantigen. - Google Patents

Verwendung von müllerscher inhibierender substanz zur behandlung von tumoren und zur modulation der expression von klasse 1-haupthistokompatibilitätsantigen.

Info

Publication number
EP0646010A4
EP0646010A4 EP93916585A EP93916585A EP0646010A4 EP 0646010 A4 EP0646010 A4 EP 0646010A4 EP 93916585 A EP93916585 A EP 93916585A EP 93916585 A EP93916585 A EP 93916585A EP 0646010 A4 EP0646010 A4 EP 0646010A4
Authority
EP
European Patent Office
Prior art keywords
major histocompatibility
antigen expression
inhibiting substance
treating tumors
histocompatibility antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93916585A
Other languages
English (en)
French (fr)
Other versions
EP0646010A1 (de
Inventor
Patricia K Donahoe
Tai Wai Chin
Robert L Parry
James Epstein
Richard C Ragin
David T Maclaughlin
Edward M Barksdale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of EP0646010A1 publication Critical patent/EP0646010A1/de
Publication of EP0646010A4 publication Critical patent/EP0646010A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
EP93916585A 1992-06-19 1993-06-18 Verwendung von müllerscher inhibierender substanz zur behandlung von tumoren und zur modulation der expression von klasse 1-haupthistokompatibilitätsantigen. Withdrawn EP0646010A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US90163792A 1992-06-19 1992-06-19
US901637 1992-06-19
US712593A 1993-01-21 1993-01-21
US7125 1993-01-21
PCT/US1993/005791 WO1994000133A1 (en) 1992-06-19 1993-06-18 Use of mullerian inhibiting substance for treating tumors and for modulating class 1 major histocompatibility antigen expression

Publications (2)

Publication Number Publication Date
EP0646010A1 EP0646010A1 (de) 1995-04-05
EP0646010A4 true EP0646010A4 (de) 1997-04-23

Family

ID=26676562

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93916585A Withdrawn EP0646010A4 (de) 1992-06-19 1993-06-18 Verwendung von müllerscher inhibierender substanz zur behandlung von tumoren und zur modulation der expression von klasse 1-haupthistokompatibilitätsantigen.

Country Status (2)

Country Link
EP (1) EP0646010A4 (de)
WO (1) WO1994000133A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5558241A (en) * 1994-01-06 1996-09-24 Temp Top Container Systems, Inc. Cryotransport chamber
DE19707497A1 (de) * 1996-08-16 1998-02-19 Boehringer Mannheim Gmbh Reaktionsbeutelvorrichtung zur Durchführung von mehrstufigen Kultivierungs/Separations-Vorgängen und/oder Reaktionen
WO2001055212A2 (en) 2000-01-27 2001-08-02 The General Hospital Corporation Delivery of therapeutic biological from implantable tissue matrices
US20100233689A1 (en) 2007-03-22 2010-09-16 The General Hospital Corporation Pyrazoloanthrone and derivatives thereof for the treatment of cancer expressing 'mullerian inhibiting substance' type ii receptor (misrii) and of excess androgen states
EP2190481B1 (de) 2007-07-17 2014-12-24 The General Hospital Corporation Verfahren zur identifizierung und anreicherung von populationen von eierstockkrebs-stammzellen und somatischen eierstock-stammzellen und ihre verwendungen

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011687A (en) * 1984-06-18 1991-04-30 The General Hospital Corporation Purified Mullerian inhibiting substance and process for treating human ovarian cancer cells
WO1992007943A1 (en) * 1990-10-31 1992-05-14 Somatix Therapy Corporation Retroviral vectors useful for gene therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0437427A4 (en) * 1985-10-30 1992-07-01 Biogen, Inc. Cleaved dimers of mullerian inhibiting substance-like polypeptides
JPH06510022A (ja) * 1991-04-12 1994-11-10 ザ・ジェネラル・ホスピタル・コーポレーション ある種の腫瘍の治療のためのミュラー阻害物質の使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011687A (en) * 1984-06-18 1991-04-30 The General Hospital Corporation Purified Mullerian inhibiting substance and process for treating human ovarian cancer cells
WO1992007943A1 (en) * 1990-10-31 1992-05-14 Somatix Therapy Corporation Retroviral vectors useful for gene therapy

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CATE R.L. ET AL.: "Isolation of the bovine and human genes for Müllerian Inhibiting Substance and expression of the human gene in animal cells.", CELL, vol. 45, June 1986 (1986-06-01), pages 685 - 698, XP002024939 *
MACLAUGHLIN D.T.: "Mullerian duct regression and antiproliferative bioactivities of Mullerian Inhibiting Substance reside in its carboxy-terminal domain.", ENDOCRINOLOGY, vol. 131, no. 1, July 1992 (1992-07-01), pages 291 - 296, XP000644378 *
PEPINSKY R.B. ET AL.: "Proteolytic processing of Mullerian Inhibiting Substance produces a transforming growth factor-beta-like fragment.", J.BIOL.CHEM., vol. 263, no. 35, 1988, pages 18961 - 18964, XP002024938 *
RAGIN R.C.: "Human Mullerian Inhibiting Substance: Enhanced purification imparts biochemical stability and restores antiproliferation effect.", PROTEIN EXPRESSION AND PURIFICATION, vol. 3, no. 3, 22 June 1992 (1992-06-22), pages 236 - 245, XP000644388 *
See also references of WO9400133A1 *

Also Published As

Publication number Publication date
EP0646010A1 (de) 1995-04-05
WO1994000133A1 (en) 1994-01-06

Similar Documents

Publication Publication Date Title
EP0534166A3 (en) Procedure and apparatus for the quantitative determination of optic active substances
GB2242358B (en) Cosmetic formulation containing a carrier and a water-in-oil emulsion
ZA977087B (en) Methods of cancer treatment using naaladase inhibitors
FR2695027B1 (fr) Agrafe chirurgicale et appareil pour son impaction.
EP0831880A4 (de) Antikörper und deren fragmente zur hemmung von tumorwachstum
HUP9902068A3 (en) Methods and compositions for the diagnosis and treatment of cancer
GB9927379D0 (en) Emulsion for well and formation treatment
EP0861539A4 (de) Effiziente kryptographische hash-funktionen und verfahren zur vergrösserung der sicherheit der hash-funktionen und der pseudozufallsfunktionen
IL85430A (en) Ultra-violet device and its use for sterilising objects
DZ1741A1 (fr) Méthode et dispositif pour la décomposition pyrolitique d'hydrocarbures.
EP0640097A4 (de) Zusammensetzung und methoden zur impfung gegen coronaviren(20.01.94).
EP0655261A3 (de) Verfahren zur Verringerung des Haarausfalls und zur Förderung des Haarwachstums.
IL96915A0 (en) Method and apparatus for fragmentation of hard substances within the human body
EP0758196A4 (de) Zusammensetzungen und verfahren zur tumorbehandlung
IL127605A0 (en) Methods of cancer treatment using naaladase inhibitors
ZA933255B (en) Preserved polysiloxane emulsions for treating tissues
ZA954984B (en) Compositions and methods for the treatment of tumors
IL127739A0 (en) Retinoyloxy (substituted) alkylene butyrates useful for the treatment of cancer and other proliferative diseases
EP0646010A4 (de) Verwendung von müllerscher inhibierender substanz zur behandlung von tumoren und zur modulation der expression von klasse 1-haupthistokompatibilitätsantigen.
IL115320A0 (en) Retinoyloxy (substituted) methyl butyrates useful for the treatment of cancer and other proliferative diseases
AU4953693A (en) Antibody/radioisotope conjugate for tumor diagnosis and/or therapy
GB9010058D0 (en) Method and composition for the treatment of cancer
EP0733365A3 (de) Verwendung von Benzochinolin-3-one zur Behandlung und Vorbeugung von Prostatkarzinom
EP0604717A3 (de) Verfahren zur dauerhaften Haarverformung und Mittel zur Durchführung dieses Verfahrens.
NO913995L (no) Inhibitorer for dannelse av tumornekrosefaktor samt fremgangsmaate og anvendelse derav

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950118

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): CH DE DK ES FR GB IE IT LI NL PT SE

RHK1 Main classification (correction)

Ipc: C12N 15/16

A4 Supplementary search report drawn up and despatched

Effective date: 19970306

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): CH DE DK ES FR GB IE IT LI NL PT SE

17Q First examination report despatched

Effective date: 19991221

RTI1 Title (correction)

Free format text: USE OF MULLERIAN INHIBITING SUBSTANCE FOR TREATING TUMORS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 48/00 20060101ALI20060215BHEP

Ipc: C12N 15/86 20060101ALI20060215BHEP

Ipc: C12N 5/10 20060101ALI20060215BHEP

Ipc: C12N 15/16 20060101AFI20060215BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE GENERAL HOSPITAL CORPORATION

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060704